Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-25
2006-07-25
Owens, Amelia A. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S269000
Reexamination Certificate
active
07081474
ABSTRACT:
Peripherally administered Brefeldin A and its analogs and derivatives are used to enhance learning and reverse memory dysfunction through induced long term potentiation in hippocampal issues.
REFERENCES:
patent: 5214039 (1993-05-01), Kawaguchi et al.
patent: 5242932 (1993-09-01), Gandy et al.
patent: 3247379 (1984-06-01), None
patent: 4305249 (1994-08-01), None
patent: 0230967 (1987-08-01), None
patent: 57159710 (1982-10-01), None
Boast and Abou-Gharbia, Immune-Directed Mechanisms in Alzheimer's Disease, DN&P, 6(7):564, 1993.
N.R. Carlson, Foundationsl of Physiological Psychology, “Chapter 12: Learning and Memory,” 2nd Edition, Allyn & Bacon: Boston, 1992, pp. 421-430.
Caporaso, et al., Morphologic and Biochemical Analysis of the Intracellular Trafficking of the Alzheimer beta/A4 Amyloid Precursor Protein, Journal of Neuroscience, 14(5 Pt 2):3122, May 1994.
Caporaso, et al., Protein Phosphorylation Regulates the Cellular Trafficking and Processing of the Alzheimer Beta/A4 Amyloid Precursor Protein, Molecular Mechanisms of Membrane Traffic, NATO ASI Series, vol. H74, 1993.
Caporaso, et al., Chloroquine Inhibits Intracellular Degradation But Not Secretion of Alzheimer beta/A4 Amyloid Precursor Protein, Proceedings of the National Academy of Sciences of the U.S., 89(6):2252, Apr. 5, 1992.
Dyrks, et al., Generation of βA4 from the amyloid protein precursor and fragments thereof, FEBS 13297, 335(1):89, 1993.
Carol Ezzell, “Neuroscientists Lay The Groundwork for Détente In the Battle of Learning and Memory Research”, The Jrnl. Of NIH Research, 4:60-64, Nov. 1992.
Gabuzada, D., et al., Inhibition of Energy Metabolism Alters the Processing of Amyloid Precursor Protein and Induces a Potentially Amyloidogenic Derivative, Journal of Biological Chemistry, 269(18):13623-8, May 6, 1994.
Gourmelon, et al., “Action of 1,4-diacid anydrides on m-disubsituted aromatic compounds, (Abstract No. 135556d, XP002035950)”,. Chemical Abstracts 81(21) (Nov. 25, 1974).
Haass, et al., β-Amyloid Peptide and a 3-kDa Fragment are Derived by Distinct Cellular Mechanisms, J. Biol. Chem., 268(5):3021, 1993.
Haass, et al., Normal Cellular Processing of a beta-Amyloid Precursor Protein Results in the Secretion of the Ayloid beta peptide and Related Molecules, Annals of the N.Y. Acad. of Sciences, 695:109-116, Sep. 24, 1993.
Rachel Nowak, “Corners of the Mind: The Cellular Basis of Memory and Learning,” The Jrnl. Of NIH Research, 4:49-55, Jan. 1992.
Nguyen et al., Requirement of a Critical Period of Transcription for Induction of a Late Phase of LTP, Science, 265:1104-1107, Aug. 19, 1994.
Rockefeller University, “APP Modulators for the Treatment of Amyloidosis”, Curr. Opin. Ther. Pat., 4/1:77, 1994.
Takashi, et al., “Ascotoxin” (Abstract No. 71697n, XP002045314)., Chemical Abstracts 76(13) (Mar. 27, 1972).
Ito Ken-Ichi
McGaugh James L.
Sumikawa Katumi
Morrison & Foerster / LLP
Owens Amelia A.
The Regents of the University of California
LandOfFree
Drugs to improve synaptic transmission does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drugs to improve synaptic transmission, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drugs to improve synaptic transmission will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3613143